Skip to main content
Pharmacokinetics and metabolism of 2-aminothiazoles with antiprion activity in mice.
- Author(s): Silber, B Michael;
- Rao, Satish;
- Fife, Kimberly L;
- Gallardo-Godoy, Alejandra;
- Renslo, Adam R;
- Dalvie, Deepak K;
- Giles, Kurt;
- Freyman, Yevgeniy;
- Elepano, Manuel;
- Gever, Joel R;
- Li, Zhe;
- Jacobson, Matthew P;
- Huang, Yong;
- Benet, Leslie Z;
- Prusiner, Stanley B
- et al.
Published Web Locationhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC3640342/
No data is associated with this publication.
PurposeTo discover drugs lowering PrP(Sc) in prion-infected cultured neuronal cells that achieve high concentrations in brain to test in mouse models of prion disease and then treat people with these fatal diseases.
MethodsWe tested 2-AMT analogs for EC50 and PK after a 40 mg/kg single dose and 40-210 mg/kg/day doses for 3 days. We calculated plasma and brain AUC, ratio of AUC/EC50 after dosing. We reasoned that compounds with high AUC/EC50 ratios should be good candidates going forward.
ResultsWe evaluated 27 2-AMTs in single-dose and 10 in 3-day PK studies, of which IND24 and IND81 were selected for testing in mouse models of prion disease. They had high concentrations in brain after oral dosing. Absolute bioavailability ranged from 27-40%. AUC/EC50 ratios after 3 days were >100 (total) and 48-113 (unbound). Stability in liver microsomes ranged from 30->60 min. Ring hydroxylated metabolites were observed in microsomes. Neither was a substrate for the MDR1 transporter.
ConclusionsIND24 and IND81 are active in vitro and show high AUC/EC50 ratios (total and unbound) in plasma and brain. These will be evaluated in mouse models of prion disease.
Item not freely available? Link broken?Report a problem accessing this item